Evidence map›Paper›PMID 29217528›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Sarah E Josefsson, Kanutte Huse, Arne Kolstad, Klaus Beiske, Daniela Pende, Chloé B Steen, Else Marit Inderberg, Ole Christian Lingjærde, Bjørn Østenstad, Erlend B Smeland and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Sarah E JosefssonCentre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Kanutte HuseCentre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Arne KolstadDepartment of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
Klaus BeiskeDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Daniela PendeImmunology Laboratory, Ospedale Policlinico San Martino, Genova, Italy.
Chloé B SteenCentre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Else Marit InderbergDepartment of Cellular Therapy, Oslo University Hospital, Oslo, Norway.
Ole Christian LingjærdeCentre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Bjørn ØstenstadDepartment of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
Erlend B SmelandCentre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Ronald LevyDivision of Oncology, Stanford School of Medicine, Stanford, California.
Jonathan M IrishDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee.
June H MyklebustCentre for Cancer Biomedicine, University of Oslo, Oslo, Norway. junehm@rr-research.no.
Oslo University Hospital · NO

Funding

Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the HostR35CA197353 · NCI · STANFORD UNIVERSITY · PI LEVY, RONALD · 2016 to 2022
$6.1M
Targeting the B Cell Receptor Signaling Network in LymphomaR00CA143231 · NCI · VANDERBILT UNIVERSITY · PI IRISH, JONATHAN MICHAEL · 2012 to 2014
$715k
NCI NIH HHS R00 CA143231NCI NIH HHS R35 CA197353
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, Differentiation, T-LymphocyteCD8-Positive T-LymphocytesCytokinesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphoma, FollicularReceptors, Antigen, T-CellReceptors, ImmunologicSignal TransductionT Lineage-Specific Activation Antigen 1T-Lymphocyte SubsetsTumor MicroenvironmentAntigens, Differentiation, T-LymphocyteCytokinesReceptors, Antigen, T-CellReceptors, ImmunologicTIGIT protein, humanT Lineage-Specific Activation Antigen 1

Identifiers

PMID29217528
PMCPMC5815910
OpenAlexW2773621976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.